サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428260

JAK阻害薬の世界市場レポート 2024

Janus Kinase (JAK) Inhibitors Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
JAK阻害薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

JAK阻害薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には18.3%の年間複合成長率（CAGR）で399億2,000万米ドルに成長すると予想されます。予測期間で予想される成長は、バイオ医薬品の研究開発の拡大、特定の適応症におけるJAK阻害薬の規制当局の承認、JAK阻害薬の臨床試験の範囲の拡大、個別化された精密医療の進歩、併用療法におけるJAK阻害薬の採用、自己免疫ケアにおけるデジタルヘルステクノロジーの統合などによるものと考えられます。併用療法における阻害薬の使用、および自己免疫ケアにおけるデジタルヘルステクノロジーの統合。予測期間中に予想される注目すべき動向には、安全性プロファイルを改善するための新規の選択的 JAK阻害薬の開発への重点の強化、徐放性製剤を備えたJAK阻害薬の創出、JAK阻害薬の創薬における人工知能の統合、新規ドラッグデリバリーシステムにおけるJAK阻害薬の探索、製薬会社と研究機関との共同作業などが含まれています。

予想される自己免疫疾患の増加により、JAK阻害薬市場の成長が促進される見込みです。自己免疫疾患は、異常な免疫応答を特徴とするさまざまな疾患を含み、免疫系が誤って攻撃し、健康な細胞、組織、臓器に損傷を与える結果となります。 JAK阻害薬は、免疫系を調節し、炎症を軽減し、関節リウマチなどの症状を軽減することにより、自己免疫疾患の治療上の利点に貢献します。たとえば、2022年 12月の時点で、国立乾癬財団のデータによると、米国では800万人以上、世界中では1億2,500万人以上が乾癬に罹患しており、これは世界人口の2～3%を占めています。さらに、2022年9月、米国疾病管理予防センターは、米国人口の8.7%を占める2,870万人が糖尿病と診断され、そのうち5.7%がインスリンを必要とする1型糖尿病であると診断されたと報告しました。その結果、自己免疫疾患の急増がJAK阻害薬市場の成長を促進します。

個別化医療に対する需要の高まりが、JAK阻害薬市場の成長を促進すると予想されます。個人の遺伝子やタンパク質に関する知識を利用して病気を予防、検出、治療する個別化医療は、特定のシグナル伝達経路を標的とするため、JAK阻害薬に適用されます。このアプローチは、個々の遺伝子プロファイルと分子プロファイルに基づいて、自己免疫疾患や特定のがんに合わせた治療オプションを提供します。特に、2022年に個別化医療連合は、米国食品医薬品局（FDA）が12の個別化医療を承認し、これが新たに承認されたすべての治療用分子実体の約34％を構成すると報告しました。したがって、個別化医療に対する需要の高まりがJAK阻害薬市場の成長を支えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のJAK阻害薬市場、阻害薬タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ルキソリチニブ
  • トファシチニブ
  • オクラシチニブ
  • バリシチニブ
  • ペフィシチニブ
  • その他
  • 世界のJAK阻害薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 注射
  • 経口
  • その他
  • 世界のJAK阻害薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のJAK阻害薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 自己免疫疾患
  • 腫瘍
  • 炎症性疾患
  • 代謝障害

第7章 地域および国の分析

  • 世界のJAK阻害薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のJAK阻害薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • JAK阻害薬市場の競合情勢
  • JAK阻害薬市場の企業プロファイル
    • Pfizer Inc.
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis AG
    • Sanofi SA

第31章 その他の大手および革新的な企業

  • Bristol Myers Squibb Co.
  • GSK Plc.
  • Takeda Pharmaceutical Company Ltd.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • Boehringer Ingelheim Group
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Mitsubishi Tanabe Pharma Corporation
  • Incyte Corporation
  • Kyowa Hakko Kirin Co. Ltd.
  • Galapagos NV
  • Sierra Oncology Inc.
  • Dizal Pharmaceutical

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14104

Janus Kinase (JAK) inhibitors constitute a drug class that inhibits the activity of Janus Kinase enzymes. These inhibitors find application in the treatment of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondylarthritis, ulcerative colitis, atopic dermatitis, and alopecia areata.

The JAK inhibitors encompass medications such as ruxolitinib, tofacitinib, oclacitinib, baricitinib, peficitinib, and others. Ruxolitinib, for example, is a JAK inhibitor primarily employed in the treatment of myelofibrosis, a rare bone marrow disorder, and polycythemia vera, characterized by the excessive production of red blood cells. These inhibitors can be administered through various routes, including injectable, oral, and others. They are available through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to a range of applications, including autoimmune disorders, oncology, inflammatory disorders, and metabolic disorders.

The janus kinas (JAK) inhibitors market research report is one of a series of new reports from The Business Research Company that provides janus kinas (JAK) inhibitors market statistics, including janus kinas (JAK) inhibitors industry global market size, regional shares, competitors with a janus kinas (JAK) inhibitors market share, detailed janus kinas (JAK) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the janus kinas (JAK) inhibitors industry. This janus kinas (JAK) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The janus kinase (jak) inhibitors market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $20.41 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%. The growth observed in the historical period can be ascribed to the acknowledgment of the significance of the JAK-STAT signaling pathway in diseases, a rise in the prevalence of autoimmune disorders, unfulfilled medical requirements in rheumatology and dermatology, the emergence of targeted therapies for inflammatory conditions, and advancements in diagnostic capabilities for autoimmune diseases.

The janus kinase (jak) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $39.92 billion in 2028 at a compound annual growth rate (CAGR) of 18.3%. The anticipated growth in the forecast period can be ascribed to the expansion of biopharmaceutical research and development, regulatory approvals for JAK inhibitors in specific indications, the widening scope of clinical trials for JAK inhibitor drugs, advancements in personalized and precision medicine, the adoption of JAK inhibitors in combination therapies, and the integration of digital health technologies in autoimmune care. Notable trends expected in the forecast period include a heightened focus on developing novel selective JAK inhibitors for improved safety profiles, the creation of JAK inhibitors with extended-release formulations, the integration of artificial intelligence in JAK inhibitor drug discovery, exploration of JAK inhibitors in novel drug delivery systems, and collaborative efforts between pharmaceutical companies and research institutions.

The anticipated rise in autoimmune diseases is poised to drive the growth of the Janus kinase (JAK) inhibitors market. Autoimmune diseases, encompassing a diverse range of disorders characterized by an aberrant immune response, result in the immune system erroneously attacking and causing harm to healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors contribute therapeutic benefits to autoimmune diseases by modulating the immune system, mitigating inflammation, and alleviating symptoms such as rheumatoid arthritis. For example, as of December 2022, data from the National Psoriasis Foundation revealed that psoriasis affected over 8 million people in the United States and 125 million individuals worldwide, constituting 2 to 3% of the global population. Additionally, in September 2022, the Centers for Disease Control and Prevention reported that diabetes was diagnosed in 28.7 million individuals, accounting for 8.7% of the U.S. population, with 5.7% of those diagnosed having type 1 diabetes requiring insulin. Consequently, the surge in autoimmune disease instances propels the Janus kinase (JAK) inhibitors market's growth.

The increasing demand for personalized medicine is set to drive the growth of the Janus kinase (JAK) inhibitors market. Personalized medicine, involving the use of knowledge about an individual's genes or proteins to prevent, detect, or treat diseases, finds application in Janus kinase (JAK) inhibitors as they target specific signaling pathways. This approach offers tailored treatment options for autoimmune disorders and certain cancers based on individual genetic and molecular profiles. Notably, in 2022, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the escalating demand for personalized medicine underpins the growth of the Janus kinase (JAK) inhibitors market.

Product innovation stands out as a prominent trend gaining traction in the Janus kinase (JAK) inhibitors market. Major players in the Janus kinase (JAK) inhibitors market are dedicated to introducing technologically advanced solutions to maintain their market positions. For example, in May 2022, Eli Lilly and Company, a U.S.-based pharmaceutical company, and Incyte, a Switzerland-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of OLUMIANT (baricitinib). OLUMIANT is the first and only FDA-approved JAK inhibitor for treating COVID-19 in hospitalized individuals requiring varying levels of oxygen assistance. Specifically, it is approved for use in adult hospital patients with extracorporeal membrane oxygenation (ECMO), non-invasive or invasive mechanical breathing, or COVID-19 disease 2019 (COVID-19).

Major companies operating in the Janus kinase (JAK) inhibitors market are intensifying their focus on introducing innovative formulations, such as topical medications, to gain a competitive edge. Topical medications are applied to localized areas of the body, typically the skin or mucous membranes, to treat specific conditions or provide protection. In July 2022, Incyte Corporation, a U.S.-based pharmaceutical company, obtained approval from the U.S. FDA for its Opzelura (ruxolitinib) cream, the first FDA-approved treatment for repigmentation in patients with non-segmental vitiligo. Opzelura is a novel formulation of ruxolitinib, a selective JAK1/JAK2 inhibitor developed by Incyte. The FDA approval was based on findings from the Phase III TRuE-V clinical trial program, including studies TRuE-V1 and TRuE-V2, evaluating the safety and effectiveness of ruxolitinib cream in vitiligo patients.

In January 2023, Sun Pharma Ltd., an India-based pharmaceutical company, completed the acquisition of Concert Pharmaceuticals Inc. for $576 million, adding deuruxolitinib, a JAK inhibitor used to treat alopecia areata, to Sun Pharma Ltd.'s portfolio. Concert Pharmaceuticals Inc. is a U.S.-based biotech company specializing in the development of Janus kinase (JAK) inhibitors.

Major companies operating in the janus kinase (jak) inhibitors market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., GSK Plc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Co., Gilead Sciences Inc., Boehringer Ingelheim Group, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Incyte Corporation, Kyowa Hakko Kirin Co. Ltd., Galapagos NV, Sierra Oncology Inc., Dizal Pharmaceutical, Reistone Biopharma Co. Ltd., CTI BioPharma Corp., Celon Pharma SA, Theravance Biopharma Inc., Aclaris Therapeutics Inc., Alexion Pharmaceuticals Inc.

North America was the largest region in the Janus kinase (JAK) inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the janus kinase (jak) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the janus kinase (jak) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The Janus kinase (JAK) inhibitors market consists of sales of xeljanz, cibinqo, rinvoq and jyseleca. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Janus Kinase (JAK) Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on janus kinase (jak) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for janus kinase (jak) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The janus kinase (jak) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Inhibitors Type: Ruxolitinib; Tofacitinib; Oclacitinib; Baricitinib; Peficitinib; Other Inhibitor Types
  • 2) By Mode Of Administration: Injectable; Oral; Other Modes Of Administration
  • 3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
  • 4) By Application: Autoimmune Disorders; Oncology; Inflammatory Disorders; Metabolic Disorders
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi SA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Janus Kinase (JAK) Inhibitors Market Characteristics

3. Janus Kinase (JAK) Inhibitors Market Trends And Strategies

4. Janus Kinase (JAK) Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Janus Kinase (JAK) Inhibitors Market Size and Growth

  • 5.1. Global Janus Kinase (JAK) Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Janus Kinase (JAK) Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Janus Kinase (JAK) Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Janus Kinase (JAK) Inhibitors Market Segmentation

  • 6.1. Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ruxolitinib
  • Tofacitinib
  • Oclacitinib
  • Baricitinib
  • Peficitinib
  • Other Inhibitor Types
  • 6.2. Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectable
  • Oral
  • Other Modes Of Administration
  • 6.3. Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • 6.4. Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Autoimmune Disorders
  • Oncology
  • Inflammatory Disorders
  • Metabolic Disorders

7. Janus Kinase (JAK) Inhibitors Market Regional And Country Analysis

  • 7.1. Global Janus Kinase (JAK) Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Janus Kinase (JAK) Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Janus Kinase (JAK) Inhibitors Market

  • 8.1. Asia-Pacific Janus Kinase (JAK) Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Janus Kinase (JAK) Inhibitors Market

  • 9.1. China Janus Kinase (JAK) Inhibitors Market Overview
  • 9.2. China Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Janus Kinase (JAK) Inhibitors Market

  • 10.1. India Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Janus Kinase (JAK) Inhibitors Market

  • 11.1. Japan Janus Kinase (JAK) Inhibitors Market Overview
  • 11.2. Japan Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Janus Kinase (JAK) Inhibitors Market

  • 12.1. Australia Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Janus Kinase (JAK) Inhibitors Market

  • 13.1. Indonesia Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Janus Kinase (JAK) Inhibitors Market

  • 14.1. South Korea Janus Kinase (JAK) Inhibitors Market Overview
  • 14.2. South Korea Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Janus Kinase (JAK) Inhibitors Market

  • 15.1. Western Europe Janus Kinase (JAK) Inhibitors Market Overview
  • 15.2. Western Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Janus Kinase (JAK) Inhibitors Market

  • 16.1. UK Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Janus Kinase (JAK) Inhibitors Market

  • 17.1. Germany Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Janus Kinase (JAK) Inhibitors Market

  • 18.1. France Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Janus Kinase (JAK) Inhibitors Market

  • 19.1. Italy Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Janus Kinase (JAK) Inhibitors Market

  • 20.1. Spain Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Janus Kinase (JAK) Inhibitors Market

  • 21.1. Eastern Europe Janus Kinase (JAK) Inhibitors Market Overview
  • 21.2. Eastern Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Janus Kinase (JAK) Inhibitors Market

  • 22.1. Russia Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Janus Kinase (JAK) Inhibitors Market

  • 23.1. North America Janus Kinase (JAK) Inhibitors Market Overview
  • 23.2. North America Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Janus Kinase (JAK) Inhibitors Market

  • 24.1. USA Janus Kinase (JAK) Inhibitors Market Overview
  • 24.2. USA Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Janus Kinase (JAK) Inhibitors Market

  • 25.1. Canada Janus Kinase (JAK) Inhibitors Market Overview
  • 25.2. Canada Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Janus Kinase (JAK) Inhibitors Market

  • 26.1. South America Janus Kinase (JAK) Inhibitors Market Overview
  • 26.2. South America Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Janus Kinase (JAK) Inhibitors Market

  • 27.1. Brazil Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Janus Kinase (JAK) Inhibitors Market

  • 28.1. Middle East Janus Kinase (JAK) Inhibitors Market Overview
  • 28.2. Middle East Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Janus Kinase (JAK) Inhibitors Market

  • 29.1. Africa Janus Kinase (JAK) Inhibitors Market Overview
  • 29.2. Africa Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Janus Kinase (JAK) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Janus Kinase (JAK) Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Janus Kinase (JAK) Inhibitors Market Competitive Landscape
  • 30.2. Janus Kinase (JAK) Inhibitors Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi SA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Janus Kinase (JAK) Inhibitors Market Other Major And Innovative Companies

  • 31.1. Bristol Myers Squibb Co.
  • 31.2. GSK Plc.
  • 31.3. Takeda Pharmaceutical Company Ltd.
  • 31.4. Eli Lilly and Co.
  • 31.5. Gilead Sciences Inc.
  • 31.6. Boehringer Ingelheim Group
  • 31.7. Teva Pharmaceutical Industries Ltd.
  • 31.8. Astellas Pharma Inc.
  • 31.9. AstraZeneca PLC
  • 31.10. Mitsubishi Tanabe Pharma Corporation
  • 31.11. Incyte Corporation
  • 31.12. Kyowa Hakko Kirin Co. Ltd.
  • 31.13. Galapagos NV
  • 31.14. Sierra Oncology Inc.
  • 31.15. Dizal Pharmaceutical

32. Global Janus Kinase (JAK) Inhibitors Market Competitive Benchmarking

33. Global Janus Kinase (JAK) Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Janus Kinase (JAK) Inhibitors Market

35. Janus Kinase (JAK) Inhibitors Market Future Outlook and Potential Analysis

  • 35.1 Janus Kinase (JAK) Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Janus Kinase (JAK) Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Janus Kinase (JAK) Inhibitors Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer